BERN, Switzerland, April 21, 2011 /PRNewswire/ -- CSL Behring announced today that the European Commission has granted marketing authorization for Hizentra(R) (Human Normal Immunoglobulin), 20 percent solution for subcutaneous injection, for treating patients diagnosed with primary immunodeficiency (PI) as well as secondary immunodeficiencies. This authorization is valid for all 29 European/European Economic Area member states.

CSL Behring is a subsidiary of CSL Limited . Hizentra is currently marketed in the United States. It received U.S. Food and Drug Administration approval in March 2010.

LONDON, April 21, 2011 /PRNewswire/ -- Proposed changes to the immigration rules will not actually target sham colleges, instead the changes will shut down legitimate private education providers. This feeling is wide spread throughout the coalition Government and the Association of UK Private Schools and Colleges (AUKPSC). The colleges have invested a lot of time and money to gain accreditation and licensing and are now left with the prospect of losing everything.

BRUSSELS, April 20, 2011 /PRNewswire/ -- Every person's intestinal system falls into one of three clearly distinguishable types of gut microbiota, comparable to blood types. These types are not related to race, native country or diet, according to a new metagenomics study by an international consortium of scientists including Jeroen Raes, of the VIB and Vrije Universiteit Brussel, published in Nature. Metagenomics is the study of the genetic material of complete ecosystems, in this case the human gut.

LIMBURGERHOF, Germany, April 19, 2011 /PRNewswire/ -- April 25th marks the fourth annual  World Malaria Day, again to focus on the goal of achieving near zero malaria deaths by 2015, and how different stakeholders are contributing to reaching this target.    BASF is marking the day by telling the story of how a simple initiative can stop the spread of the disease, one step at a time. 

LONDON, April 19, 2011 /PRNewswire/ -- In a report published today, the European Alliance For Access to Safe Medicines (EAASM) has uncovered very serious consequences for patient safety when health care decisions are not made in the best interest of the patient, but as a result of cost cutting allowed by regulatory vagaries and loopholes. 

WASHINGTON D.C., April 18, 2011 /PRNewswire/ -- In Washington DC today, eight Supreme Court justices heard oral argument of the appeal for i4i v Microsoft. Microsoft has asked the Supreme Court to lower the standard of proof, for challenges to the validity of a properly issued patent, from clear and convincing evidence to a preponderance of evidence.

Seth Waxman, of WilmerHale, who was Solicitor General in the Clinton Administration, argued on behalf of i4i. The United States argued in favor of i4i's position, and was represented by Malcolm L. Stewart, Deputy Solicitor General.